查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1487571

生物工程蛋白药物市场（疾病：癌症、糖尿病、自体免疫疾病、传染病、造血、CVD、神经退化性疾病等）- 2024-2034 年全球产业分析、规模、份额、成长、趋势和预测

Bioengineered Protein Drugs Market (Disease Condition: Cancer, Diabetes, Autoimmune Disorder, Infectious Disease, Hematopoiesis, CVD, Neurodegenerative, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2034
出版日期: | 出版商: Transparency Market Research | 英文 202 Pages | 商品交期: 2-10个工作天内

价格

生物工程蛋白药物市场 - 报告范围

TMR 关于全球生物工程蛋白药物市场的报告研究了过去以及当前的成长趋势和机会，以获得 2024 年至 2034 年预测期内市场指标的宝贵见解。 2034年期间的市场，考虑2024年为基准年，2034年为预测年。报告中也提供了2024年至2034年全球生物工程蛋白药物市场的年复合成长率（CAGR%）。

该报告是经过广泛研究后编写的。初级研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了采访。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解生物工程蛋白药物市场。

市场概况
2023年市场价值 3,471 亿美元
2034 年市场价值 6,727 亿美元
复合年增长率 6.2%

该报告深入探讨了全球生物工程蛋白药物市场的竞争格局。全球生物工程蛋白质药物市场的主要参与者已经确定，并且每个参与者都根据各种属性进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告中介绍的全球生物工程蛋白药物市场参与者的属性。

目录

第一章：前言

第 2 章：假设与研究方法

第 3 章：执行摘要：市场

第 4 章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2020-2034年市场分析与预测

第 5 章：关键见解

  • 管道分析
  • 主要产品/品牌分析
  • 主要併购
  • COVID-19 大流行对该行业的影响

第 6 章：全球市场分析与预测：按药物类型

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依药物类型，2020-2034
    • 单株抗体
      • 修美乐
      • 利妥昔单抗
      • 阿瓦斯丁
      • 赫赛汀
      • 类卡德
      • 卢森提斯
      • 恩布雷尔
      • 合纳齐斯
      • 其他的
    • 治疗性蛋白质
      • 荷尔蒙
      • 细胞因子
        • 纽普金
        • 纽拉斯塔
        • 干扰素α
        • 促红血球生成素α
        • 白血球介素
        • 其他的
    • 血液因子
    • 酵素疗法
      • 全身性酵素疗法
      • 消化酵素疗法
    • 溶栓剂
      • tPA
      • 链激酶
      • 尿激酶
    • 疫苗
  • 市场吸引力分析：按药品类型

第 7 章：全球市场分析与预测：依疾病状况

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：依疾病状况，2020-2034
    • 癌症
    • 糖尿病
    • 自体免疫疾病
    • 传染病
    • 造血作用
    • CVD
    • 神经退化性疾病
    • 其他的
  • 市场吸引力分析：按疾病状况

第 8 章：全球市场分析与预测：按最终用户

  • 简介与定义
  • 主要发现/进展
  • 市场价值预测：按最终用户，2020-2034
    • 製药和生物技术公司
    • 合约研究组织
    • 研究机构
  • 市场吸引力分析：按最终用户

第 9 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2020-2034
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第 10 章：北美市场分析与预测

第 11 章：欧洲市场分析与预测

第 12 章：亚太市场分析与预测

第 13 章：拉丁美洲市场分析与预测

第 14 章：中东和非洲市场分析与预测

第15章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：依公司分类（2023）
  • 公司简介
    • Abbott
    • Amgen Inc.
    • Bayer AG
    • Biocon
    • Dr. Reddy's Laboratories
    • Lilly
    • F. Hoffmann - La Roche Ltd.
    • Fresenius Kabi AG
    • GSK
    • Janssen Global Services
    • Merck & Co., Inc.
    • Novartis AG
    • Panacea Biotec
    • ProBioGen AG
    • Reliance Life Science
    • Sanofi
Product Code: TMRGL8188

Bioengineered Protein Drugs Market - Scope of Report

TMR's report on the global bioengineered protein drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global bioengineered protein drugs market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global bioengineered protein drugs market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the bioengineered protein drugs market.

Market Snapshot
Market Value in 2023US$ 347.1 Bn
Market Value in 2034US$ 672.7 Bn
CAGR6.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global bioengineered protein drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global bioengineered protein drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global bioengineered protein drugs market.

The report delves into the competitive landscape of the global bioengineered protein drugs market. Key players operating in the global bioengineered protein drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global bioengineered protein drugs market profiled in this report.

Key Questions Answered in Global bioengineered protein drugs Market Report:

  • What is the sales/revenue generated by bioengineered protein drugs across all regions during the forecast period?
  • What are the opportunities in the global bioengineered protein drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Bioengineered Protein Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global bioengineered protein drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global bioengineered protein drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global bioengineered protein drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Bioengineered Protein Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Bioengineered Protein Drugs Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product /Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Bioengineered Protein Drugs Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Type, 2020-2034
    • 6.3.1. Monoclonal Antibodies
      • 6.3.1.1. Humira
      • 6.3.1.2. Rituxan
      • 6.3.1.3. Avastin
      • 6.3.1.4. Herceptin
      • 6.3.1.5. Remicade
      • 6.3.1.6. Lucentis
      • 6.3.1.7. Enbrel
      • 6.3.1.8. Synazis
      • 6.3.1.9. Others
    • 6.3.2. Therapeutic Proteins
      • 6.3.2.1. Hormones
      • 6.3.2.2. Cytokines
        • 6.3.2.2.1. Neupogen
        • 6.3.2.2.2. Neulasta
        • 6.3.2.2.3. Interferon Alpha
        • 6.3.2.2.4. Erythropoietin Alpha
        • 6.3.2.2.5. Interleukin
        • 6.3.2.2.6. Others
    • 6.3.3. Blood Factor
    • 6.3.4. Enzyme Therapy
      • 6.3.4.1. Systemic Enzyme Therapy
      • 6.3.4.2. Digestive Enzyme Therapy
    • 6.3.5. Thrombolytics
      • 6.3.5.1. tPA
      • 6.3.5.2. Streptokinase
      • 6.3.5.3. Urokinase
    • 6.3.6. Vaccines
  • 6.4. Market Attractiveness Analysis, by Drug Type

7. Global Bioengineered Protein Drugs Market Analysis and Forecast, by Disease Condition

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Condition, 2020-2034
    • 7.3.1. Cancer
    • 7.3.2. Diabetes
    • 7.3.3. Autoimmune Disorder
    • 7.3.4. Infectious Disease
    • 7.3.5. Hematopoiesis
    • 7.3.6. CVD
    • 7.3.7. Neurodegenerative
    • 7.3.8. Others
  • 7.4. Market Attractiveness Analysis, by Disease Condition

8. Global Bioengineered Protein Drugs Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by End-user, 2020-2034
    • 8.3.1. Pharma and Biotech Companies
    • 8.3.2. CROs
    • 8.3.3. Research Institutes
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Bioengineered Protein Drugs Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2020-2034
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Bioengineered Protein Drugs Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Drug Type, 2020-2034
    • 10.3.1. Monoclonal Antibodies
      • 10.3.1.1. Humira
      • 10.3.1.2. Rituxan
      • 10.3.1.3. Avastin
      • 10.3.1.4. Herceptin
      • 10.3.1.5. Remicade
      • 10.3.1.6. Lucentis
      • 10.3.1.7. Enbrel
      • 10.3.1.8. Synazis
      • 10.3.1.9. Others
    • 10.3.2. Therapeutic Proteins
      • 10.3.2.1. Hormones
      • 10.3.2.2. Cytokines
        • 10.3.2.2.1. Neupogen
        • 10.3.2.2.2. Neulasta
        • 10.3.2.2.3. Interferon Alpha
        • 10.3.2.2.4. Erythropoietin Alpha
        • 10.3.2.2.5. Interleukin
        • 10.3.2.2.6. Others
    • 10.3.3. Blood Factor
    • 10.3.4. Enzyme Therapy
      • 10.3.4.1. Systemic Enzyme Therapy
      • 10.3.4.2. Digestive Enzyme Therapy
    • 10.3.5. Thrombolytics
      • 10.3.5.1. tPA
      • 10.3.5.2. Streptokinase
      • 10.3.5.3. Urokinase
    • 10.3.6. Vaccines
  • 10.4. Market Value Forecast, by Disease Condition, 2020-2034
    • 10.4.1. Cancer
    • 10.4.2. Diabetes
    • 10.4.3. Autoimmune Disorder
    • 10.4.4. Infectious Disease
    • 10.4.5. Hematopoiesis
    • 10.4.6. CVD
    • 10.4.7. Neurodegenerative
    • 10.4.8. Others
  • 10.5. Market Value Forecast, by End-user, 2020-2034
    • 10.5.1. Pharma and Biotech Companies
    • 10.5.2. CROs
    • 10.5.3. Research Institutes
  • 10.6. Market Value Forecast, by Country, 2020-2034
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Drug Type
    • 10.7.2. By Disease Condition
    • 10.7.3. By End-user
    • 10.7.4. By Country

11. Europe Bioengineered Protein Drugs Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Drug Type, 2020-2034
    • 11.3.1. Monoclonal Antibodies
      • 11.3.1.1. Humira
      • 11.3.1.2. Rituxan
      • 11.3.1.3. Avastin
      • 11.3.1.4. Herceptin
      • 11.3.1.5. Remicade
      • 11.3.1.6. Lucentis
      • 11.3.1.7. Enbrel
      • 11.3.1.8. Synazis
      • 11.3.1.9. Others
    • 11.3.2. Therapeutic Proteins
      • 11.3.2.1. Hormones
      • 11.3.2.2. Cytokines
        • 11.3.2.2.1. Neupogen
        • 11.3.2.2.2. Neulasta
        • 11.3.2.2.3. Interferon Alpha
        • 11.3.2.2.4. Erythropoietin Alpha
        • 11.3.2.2.5. Interleukin
        • 11.3.2.2.6. Others
    • 11.3.3. Blood Factor
    • 11.3.4. Enzyme Therapy
      • 11.3.4.1. Systemic Enzyme Therapy
      • 11.3.4.2. Digestive Enzyme Therapy
    • 11.3.5. Thrombolytics
      • 11.3.5.1. tPA
      • 11.3.5.2. Streptokinase
      • 11.3.5.3. Urokinase
    • 11.3.6. Vaccines
  • 11.4. Market Value Forecast, by Disease Condition, 2020-2034
    • 11.4.1. Cancer
    • 11.4.2. Diabetes
    • 11.4.3. Autoimmune Disorder
    • 11.4.4. Infectious Disease
    • 11.4.5. Hematopoiesis
    • 11.4.6. CVD
    • 11.4.7. Neurodegenerative
    • 11.4.8. Others
  • 11.5. Market Value Forecast, by End-user, 2020-2034
    • 11.5.1. Pharma and Biotech Companies
    • 11.5.2. CROs
    • 11.5.3. Research Institutes
  • 11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Type
    • 11.7.2. By Disease Condition
    • 11.7.3. By End-user
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Bioengineered Protein Drugs Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Drug Type, 2020-2034
    • 12.3.1. Monoclonal Antibodies
      • 12.3.1.1. Humira
      • 12.3.1.2. Rituxan
      • 12.3.1.3. Avastin
      • 12.3.1.4. Herceptin
      • 12.3.1.5. Remicade
      • 12.3.1.6. Lucentis
      • 12.3.1.7. Enbrel
      • 12.3.1.8. Synazis
      • 12.3.1.9. Others
    • 12.3.2. Therapeutic Proteins
      • 12.3.2.1. Hormones
      • 12.3.2.2. Cytokines
        • 12.3.2.2.1. Neupogen
        • 12.3.2.2.2. Neulasta
        • 12.3.2.2.3. Interferon Alpha
        • 12.3.2.2.4. Erythropoietin Alpha
        • 12.3.2.2.5. Interleukin
        • 12.3.2.2.6. Others
    • 12.3.3. Blood Factor
    • 12.3.4. Enzyme Therapy
      • 12.3.4.1. Systemic Enzyme Therapy
      • 12.3.4.2. Digestive Enzyme Therapy
    • 12.3.5. Thrombolytics
      • 12.3.5.1. tPA
      • 12.3.5.2. Streptokinase
      • 12.3.5.3. Urokinase
    • 12.3.6. Vaccines
  • 12.4. Market Value Forecast, by Disease Condition, 2020-2034
    • 12.4.1. Cancer
    • 12.4.2. Diabetes
    • 12.4.3. Autoimmune Disorder
    • 12.4.4. Infectious Disease
    • 12.4.5. Hematopoiesis
    • 12.4.6. CVD
    • 12.4.7. Neurodegenerative
    • 12.4.8. Others
  • 12.5. Market Value Forecast, by End-user, 2020-2034
    • 12.5.1. Pharma and Biotech Companies
    • 12.5.2. CROs
    • 12.5.3. Research Institutes
  • 12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Type
    • 12.7.2. By Disease Condition
    • 12.7.3. By End-user
    • 12.7.4. By Country/Sub-region

13. Latin America Bioengineered Protein Drugs Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Drug Type, 2020-2034
    • 13.3.1. Monoclonal Antibodies
      • 13.3.1.1. Humira
      • 13.3.1.2. Rituxan
      • 13.3.1.3. Avastin
      • 13.3.1.4. Herceptin
      • 13.3.1.5. Remicade
      • 13.3.1.6. Lucentis
      • 13.3.1.7. Enbrel
      • 13.3.1.8. Synazis
      • 13.3.1.9. Others
    • 13.3.2. Therapeutic Proteins
      • 13.3.2.1. Hormones
      • 13.3.2.2. Cytokines
        • 13.3.2.2.1. Neupogen
        • 13.3.2.2.2. Neulasta
        • 13.3.2.2.3. Interferon Alpha
        • 13.3.2.2.4. Erythropoietin Alpha
        • 13.3.2.2.5. Interleukin
        • 13.3.2.2.6. Others
    • 13.3.3. Blood Factor
    • 13.3.4. Enzyme Therapy
      • 13.3.4.1. Systemic Enzyme Therapy
      • 13.3.4.2. Digestive Enzyme Therapy
    • 13.3.5. Thrombolytics
      • 13.3.5.1. tPA
      • 13.3.5.2. Streptokinase
      • 13.3.5.3. Urokinase
    • 13.3.6. Vaccines
  • 13.4. Market Value Forecast, by Disease Condition, 2020-2034
    • 13.4.1. Cancer
    • 13.4.2. Diabetes
    • 13.4.3. Autoimmune Disorder
    • 13.4.4. Infectious Disease
    • 13.4.5. Hematopoiesis
    • 13.4.6. CVD
    • 13.4.7. Neurodegenerative
    • 13.4.8. Others
  • 13.5. Market Value Forecast, by End-user, 2020-2034
    • 13.5.1. Pharma and Biotech Companies
    • 13.5.2. CROs
    • 13.5.3. Research Institutes
  • 13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Type
    • 13.7.2. By Disease Condition
    • 13.7.3. By End-user
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Bioengineered Protein Drugs Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Drug Type, 2020-2034
    • 14.3.1. Monoclonal Antibodies
      • 14.3.1.1. Humira
      • 14.3.1.2. Rituxan
      • 14.3.1.3. Avastin
      • 14.3.1.4. Herceptin
      • 14.3.1.5. Remicade
      • 14.3.1.6. Lucentis
      • 14.3.1.7. Enbrel
      • 14.3.1.8. Synazis
      • 14.3.1.9. Others
    • 14.3.2. Therapeutic Proteins
      • 14.3.2.1. Hormones
      • 14.3.2.2. Cytokines
        • 14.3.2.2.1. Neupogen
        • 14.3.2.2.2. Neulasta
        • 14.3.2.2.3. Interferon Alpha
        • 14.3.2.2.4. Erythropoietin Alpha
        • 14.3.2.2.5. Interleukin
        • 14.3.2.2.6. Others
    • 14.3.3. Blood Factor
    • 14.3.4. Enzyme Therapy
      • 14.3.4.1. Systemic Enzyme Therapy
      • 14.3.4.2. Digestive Enzyme Therapy
    • 14.3.5. Thrombolytics
      • 14.3.5.1. tPA
      • 14.3.5.2. Streptokinase
      • 14.3.5.3. Urokinase
    • 14.3.6. Vaccines
  • 14.4. Market Value Forecast, by Disease Condition, 2020-2034
    • 14.4.1. Cancer
    • 14.4.2. Diabetes
    • 14.4.3. Autoimmune Disorder
    • 14.4.4. Infectious Disease
    • 14.4.5. Hematopoiesis
    • 14.4.6. CVD
    • 14.4.7. Neurodegenerative
    • 14.4.8. Others
  • 14.5. Market Value Forecast, by End-user, 2020-2034
    • 14.5.1. Pharma and Biotech Companies
    • 14.5.2. CROs
    • 14.5.3. Research Institutes
  • 14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Type
    • 14.7.2. By Disease Condition
    • 14.7.3. By End-user
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2023)
  • 15.3. Company Profiles
    • 15.3.1. Abbott
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Amgen Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Bayer AG
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Biocon
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Dr. Reddy's Laboratories
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Lilly
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. F. Hoffmann - La Roche Ltd.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Fresenius Kabi AG
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. GSK
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Janssen Global Services
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Merck & Co., Inc.
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Novartis AG
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Product Portfolio
      • 15.3.12.3. SWOT Analysis
      • 15.3.12.4. Financial Overview
      • 15.3.12.5. Strategic Overview
    • 15.3.13. Panacea Biotec
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Product Portfolio
      • 15.3.13.3. SWOT Analysis
      • 15.3.13.4. Financial Overview
      • 15.3.13.5. Strategic Overview
    • 15.3.14. ProBioGen AG
      • 15.3.14.1. Company Overview
      • 15.3.14.2. Product Portfolio
      • 15.3.14.3. SWOT Analysis
      • 15.3.14.4. Financial Overview
      • 15.3.14.5. Strategic Overview
    • 15.3.15. Reliance Life Science
      • 15.3.15.1. Company Overview
      • 15.3.15.2. Product Portfolio
      • 15.3.15.3. SWOT Analysis
      • 15.3.15.4. Financial Overview
      • 15.3.15.5. Strategic Overview
    • 15.3.16. Sanofi
      • 15.3.16.1. Company Overview
      • 15.3.16.2. Product Portfolio
      • 15.3.16.3. SWOT Analysis
      • 15.3.16.4. Financial Overview
      • 15.3.16.5. Strategic Overview

List of Tables

  • Table 01: Global Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020-2034
  • Table 02: Global Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2020-2034
  • Table 03: Global Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 04: Global Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Region, 2020-2034
  • Table 05: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country, 2020-2034
  • Table 06: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020-2034
  • Table 07: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2020-2034
  • Table 08: North America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 09: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 10: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020-2034
  • Table 11: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2020-2034
  • Table 12: Europe Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 13: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020-2034
  • Table 15: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2020-2034
  • Table 16: Asia Pacific Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 17: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 18: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020-2034
  • Table 19: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2020-2034
  • Table 20: Latin America Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 21: Middle East & Africa Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Middle East & Africa Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2020-2034
  • Table 23: Middle East & Africa Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by Disease Condition, 2020-2034
  • Table 24: Middle East & Africa Bioengineered Protein Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Bioengineered Protein Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Bioengineered Protein Drugs Market Revenue (US$ Mn), by Drug Type, 2023
  • Figure 03: Global Bioengineered Protein Drugs Market Value Share, by Drug Type, 2023
  • Figure 04: Global Bioengineered Protein Drugs Market Revenue (US$ Mn), by Disease Condition, 2023
  • Figure 05: Global Bioengineered Protein Drugs Market Value Share, by Disease Condition, 2023
  • Figure 06: Global Bioengineered Protein Drugs Market Revenue (US$ Mn), by End-user, 2023
  • Figure 07: Global Bioengineered Protein Drugs Market Value Share, by End-user, 2023
  • Figure 08: Global Bioengineered Protein Drugs Market Value Share, by Region, 2023
  • Figure 09: Global Bioengineered Protein Drugs Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 10: Global Bioengineered Protein Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 11: Global Bioengineered Protein Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 12: Global Bioengineered Protein Drugs Market Value Share Analysis, by Disease Condition, 2023 and 2034
  • Figure 13: Global Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition, 2024-2034
  • Figure 14: Bioengineered Protein Drugs Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 15: Global Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 16: Global Bioengineered Protein Drugs Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 17: Global Bioengineered Protein Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 18: North America Bioengineered Protein Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 19: North America Bioengineered Protein Drugs Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 20: North America Bioengineered Protein Drugs Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 21: North America Bioengineered Protein Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 22: North America Bioengineered Protein Drugs Market Value Share Analysis, by Disease Condition, 2023 and 2034
  • Figure 23: North America Bioengineered Protein Drugs Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 24: North America Bioengineered Protein Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 25: North America Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition, 2024-2034
  • Figure 26:North America Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 27: Europe Bioengineered Protein Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 28: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 29: Europe Bioengineered Protein Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 30: Europe Bioengineered Protein Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 31: Europe Bioengineered Protein Drugs Market Value Share Analysis, by Disease Condition, 2023 and 2034
  • Figure 32: Europe Bioengineered Protein Drugs Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 33: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 34: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition, 2024-2034
  • Figure 35: Europe Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 36: Asia Pacific Bioengineered Protein Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 37: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 38: Asia Pacific Bioengineered Protein Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 39: Asia Pacific Bioengineered Protein Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 40: Asia Pacific Bioengineered Protein Drugs Market Value Share Analysis, by Disease Condition, 2023 and 2034
  • Figure 41: Asia Pacific Bioengineered Protein Drugs Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 42: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 43: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition, 2024-2034
  • Figure 44: Asia Pacific Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 45: Latin America Bioengineered Protein Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 46: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 47: Latin America Bioengineered Protein Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 48: Latin America Bioengineered Protein Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 49: Latin America Bioengineered Protein Drugs Market Value Share Analysis, by Disease Condition, 2023 and 2034
  • Figure 50: Latin America Bioengineered Protein Drugs Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 51: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 52: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition, 2024-2034
  • Figure 53: Latin America Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 54: Middle East & Africa Bioengineered Protein Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 55: Middle East & Africa Bioengineered Protein Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 56: Middle East & Africa Bioengineered Protein Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 57: Middle East & Africa Bioengineered Protein Drugs Market Value Share Analysis, by Drug Type, 2023 and 2034
  • Figure 58: Middle East & Africa Bioengineered Protein Drugs Market Value Share Analysis, by Disease Condition, 2023 and 2034
  • Figure 59: Middle East & Africa Bioengineered Protein Drugs Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 60: Middle East & Africa Bioengineered Protein Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 61: Middle East & Africa Bioengineered Protein Drugs Market Attractiveness Analysis, by Disease Condition, 2024-2034
  • Figure 62: Middle East & Africa Bioengineered Protein Drugs Market Attractiveness Analysis, by End-user, 2024-2034